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Dysbiosis of the salivary microbiota 
in pediatric-onset primary 
sclerosing cholangitis and its 
potential as a biomarker
Kentaro Iwasawa  1,2,3, Wataru Suda4,5,6, Tomoyuki Tsunoda7, Manari Oikawa-Kawamoto1,8, 
Shuichiro Umetsu1, Lena Takayasu4,6, Ayano Inui1, Tomoo Fujisawa1, Hidetoshi Morita9, 
Tsuyoshi Sogo1 & Masahira Hattori4,6,10
Primary sclerosing cholangitis (PSC) is a liver disease known for its frequent concurrence with 
inflammatory bowel disease. Dysbiosis of the gut microbiota in PSC was reported in several studies, 
but the microbiological features of the salivary microbiota in PSC have not been established. Here we 
compared the salivary microbial communities of 24 pediatric-onset PSC patients, 16 age-matched 
ulcerative colitis (UC) patients, and 24 healthy controls (HCs) by analyzing the bacterial 16S rRNA gene 
sequence data. The species-richness (α-diversity) showed no significant between-group differences, 
whereas the overall salivary microbiota structure (β-diversity) showed significant differences among 
the three groups. Taxonomic assignment revealed that the PSC salivary microbiota were characterized 
by significant decreases in the abundance of Rothia and Haemophilus compared to the HC group, 
and significantly decreased Haemophilus and increased Oribacterium compared to the UC group. 
By combining the genera selected by the random forest algorithm in machine learning, followed by 
confirmation with 10-fold cross-validation, we were able to distinguish the PSC group from the HC group 
with the area under the curve (AUC) of 0.7423, and from the UC group with the AUC of 0.8756. Our results 
indicate the potential of salivary microbiota as biomarkers for a noninvasive diagnosis of PSC.
Primary sclerosing cholangitis (PSC) is a liver disease characterized by multiple stenoses due to chronic inflam-
mation and fibrosis in the intrahepatic and extrahepatic biliary system. The disease eventually progresses to 
end-stage liver disease, resulting in poor prognoses1. PSC is also known for its high association with inflam-
matory bowel disease (IBD), mainly ulcerative colitis (UC), with a prevalence of 70–80% in adults1, and with 
the same proportion or an even higher proportion in children2–4. Conversely, as many as 8.1% of IBD patients 
develop PSC5. It was also reported that PSC-like bile duct lesions occur frequently even with normal biochemical 
profiles in children with IBD6.
In light of this frequent concurrence of PSC and IBD, the diagnosis of either of these diseases should consider 
the concurrence of the other disease. Cholangiography is mandatory for the diagnosis of PSC, and endoscopic 
retrograde cholangiopancreatography (ERCP) has been used for the diagnosis of PSC in adults and children7. 
However, ERCP is associated with complications such as pancreatitis. To avoid complications, magnetic 
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resonance cholangiopancreatography (MRCP) has been proposed as an alternative method for the diagnosis 
of PSC, but its sensitivity is approximately 81–86% in children, with a lower resolution in younger patients and 
the need for sedation in some cases8,9. Thus, additional noninvasive diagnostic biomarkers are desirable for the 
evaluation of the presence of PSC.
In pediatric and adult PSC patients, the oral administration of antibiotics was reported to decrease the serum 
levels of alanine aminotransferase (ALT) and γ-glutamyltranspeptidase (GGT), with histological improve-
ment10–14, implying that gastrointestinal inflammation and indigenous microbes are associated with the patho-
genesis and prognosis of PSC, and that early intervention may also produce better prognoses. The gut microbiota 
of adult PSC patients were recently intensively evaluated by using 16S rRNA gene sequences15–23. Those studies 
indicated the enrichment of particular bacterial genera including Veillonella19,23, Enterococcus20,23, Lactobacillus20, 
Ruminococcus22, Streptococcus23, Rothia23, and Fusobacterium20,22 in the feces of PSC patients. We also reported 
the enrichment of several species, some belonging to these genera, in a Japanese pediatric-onset PSC cohort2.
In addition to close associations between dysbiosis of the gut microbiota and diseases24, several studies have 
described alterations of salivary microbiota in patients with various diseases. These include cirrhosis25, IBD26,27, 
pancreatic cancer28,29, lung cancer30, colorectal cancer31, IgA nephropathy32, celiac disease33, Behcet’s disease34, 
and rheumatoid arthritis35. The involvement of salivary microbes in these diseases is unclear, but a correlation 
between the gut and oral microbiota was suggested27,36. In addition, changes in the salivary microbiota in systemic 
diseases may be a resource of microbial biomarkers specific to the diseases, which could contribute to the devel-
opment of simple and noninvasive diagnoses based on microbial profiling with saliva samples.
To date, there has been no report on the salivary microbiota of PSC patients. As the initial step in the explo-
ration of potential biomarkers for the noninvasive diagnosis of PSC, we performed a bacterial 16S rRNA gene 
sequence analysis to characterize the salivary microbiota of pediatric-onset PSC patients in a comparison of their 
microbiota with those of pediatric-onset UC patients and healthy controls (HCs).
Results
Patients, clinical data, and healthy subjects. We recruited 24 PSC and 16 UC patients without PSC 
whose age of onset was <18 years from Saiseikai Yokohamashi Tobu Hospital (Kanagawa, Japan) between May 
2013 and October 2015, and healthy volunteers without any symptoms (Table 1). We collected salivary samples 
from 24 patients with PSC (the PSC group, median age 12.5 years), 16 patients with UC without PSC (the UC 
group, median age 12.5 years), and 24 healthy controls (the HC group, median age 11.5 years).
The diagnosis of PSC was made based on characteristic bile duct changes with multifocal strictures and seg-
mental dilatation on cholangiography, clinical presentation, and the cholestatic biochemical profile, and no evi-
dence of secondary sclerosing cholangitis7. The diagnosis of UC was made using the revised Porto criteria37.
This study was approved by the ethical committees of Saiseikai Yokohamashi Tobu Hospital, Azabu University, 
Waseda University, and the University of Tokyo, and signed informed consent was obtained from all subjects who 
provided specimens.
The collection of 16S rRNA gene sequences of salivary microbiota of the three subject groups. 
We obtained a total of 458,021 high-quality 16S reads from the three groups by using the Roche 454 platform (see 
Methods, Supplementary Table S1). Of them, we randomly selected 3,000 reads per sample, accounting for a total 
of 192,000 reads from 64 samples, and analyzed them to minimize the overestimation of the species richness in 
the clustering due to intrinsic sequencing error38. The Good’s coverage index39,40 of the 3,000 reads per sample was 
0.971, indicating a high coverage degree which was sufficient for the analysis.
Relationship between medications and phenotypes of the PSC patients with the salivary micro-
bial composition. Some of the PSC and UC patients had been treated with various medications (Table 1). 
Since we observed a significant alteration of the gut microbiota of PSC patients due to salazosulfapyridine (SASP) 
treatment2, we first evaluated the effect of medications on the salivary microbiota of the patients by comparing 
the data between those with and without medication use. The comparative analyses of the PSC samples with and 
without SASP treatment (Supplementary Table S2) revealed no significant difference between the two groups in 
the observed and Chao 1-estimated operational taxonomic units (OTU) number or in Shannon’s diversity index 
(Supplementary Fig. S1A). In addition, the weighted and unweighted UniFrac distance analyses also showed no 
significant difference between the PSC samples with and without SASP treatment (Supplementary Fig. S1B,C).
The permutational multivariate analysis of variance (PERMANOVA) also confirmed no significant difference 
between the PSC samples with and without SASP treatment, or between the PSC patients treated and untreated 
with ursodeoxycholic acid (UDCA), mesalazine, and probiotics respectively (Supplementary Table S3). In addi-
tion, the overlap with AIH and the concurrence of UC or IBD-U in the PSC patients showed no significant 
differences (Supplementary Table S3). These data suggested that the administration of these medications and the 
phenotype of PSC did not largely affect the salivary microbiota of the PSC patients. We therefore further analyzed 
all of the samples regardless of their use or non-use of medications and the phenotype of PSC.
Comparison of the salivary microbiota of the PSC, UC, and HC samples. Our comparative anal-
ysis of the PSC, UC and HC samples revealed that the observed and Chao 1-estimated OTU numbers of the 
PSC group tended to be lower than those of the UC and HC groups, without significant differences (Fig. 1A). 
Shannon’s index also showed no significant differences in bacterial diversity among the three groups (Fig. 1A).
The principal coordinate analysis (PCoA) plot based on the weighted UniFrac distance metric showed that 
many of the PSC and UC samples segregated from the HC samples, suggesting that the salivary microbiota struc-
ture of both the PSC and UC groups differed from that of the HC group (Fig. 1B). The PERMANOVA further 
revealed significant differences between the PSC and UC groups in the weighted UniFrac metric but not in the 
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unweighted UniFrac metric (Table 2). Collectively, these data suggested that the salivary microbiota of the PSC 
group exhibited microbial dysbiosis without a large alteration of the species richness, but that changes in the 
abundance of the shared species among the three groups largely contributed to the overall structural differences 
in salivary microbiota across the three groups.
We then taxonomically assigned the OTUs at the phylum and family levels according to a similarity search 
against the public databases. The taxonomic assignment indicated that the major phyla in the three groups 
were Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria, and TM7. The phylum-level 
comparison showed that the abundance of Bacteroidetes and Actinobacteria in the PSC group and the abun-
dance of Firmicutes and TM7 in the UC group differed significantly from that in the HC group (Supplementary 
Fig. S2A). At the family level, of the 14 families with the relative mean abundance of >0.5%, accounting for 
93.1% of the total abundance, the abundance of Streptococcaceae, Pasteurellaceae, and Lachnospiraceae showed 
significant differences among the three groups. Of these three families, a lower Pasteurellaceae abundance and 
a higher Lachnospiraceae abundance were observed in the PSC group compared to both the UC and HC groups 
(Supplementary Fig. S2B). The abundance of Streptococcaceae was significantly lower in only the UC group com-
pared to the HC group (Supplementary Fig. S2B).
The taxonomic assignment at the genus level identified a total of 114 bacterial genera, of which we further 
evaluated the major 16 genera with the relative mean abundances of >0.5%, accounting for 92.2% of the total 
abundance (Fig. 2). As shown in Fig. 2B, the abundances of Rothia and Haemophilus were significantly lower 
in the PSC group compared to the HC group (p = 0.0454 and 0.0036, respectively). Moreover, the abundance of 
Haemophilus was also significantly lower in the PSC group than that in the UC group (p = 0.0007). Conversely, 
the abundance of Oribacterium was significantly higher in the PSC group compared to the UC group (p = 0.0036). 
Additionally, the abundance of Streptococcus was significantly lower in the UC group compared to the HC group 
(p = 0.0159).
PSC UC HC p-value
Number of patients 24 16 24
Male, n (%) 16 (67) 7 (44) 10 (42) 0.172
Present age, yrs, median (IQR) 12.5 (9.5–17.5) 12.5 (11.5–15.5) 11.5 (5.5–16) 0.467
Age at onset, yrs, median (IQR) 6 (3–10) 11 (7.5–12.5) — 0.026
Age at diagnosis, yrs, median (IQR) 9 (6–12) 12 (9–13) — 0.161
PSC phenotype n (%)
   Large duct PSC 23 (96) — —
   Small duct PSC 1 (4) — —
   Overlap with autoimmune hepatitis 14 (58) — —
Type of IBD, n (%) 24 (100) 16 (100) — 1.000
   UC 10 (42) 16 (100) — <0.001
   IBD-U 14 (58) 0 (0) — <0.001
PUCAI score in UC patients, n (%)
   Remission (0–9) 7 (70) 8 (50) — 0.428
   Mild (10–30) 3 (30) 5 (31) — 0.945
   Moderate to severe (35–) 0 (0) 3 (19) — 0.262
Biochemical data, median (IQR)
   Platelets, 109/μL 274.5 (240.5–341.5) 270.5 (240.5–366.0) — 0.801
   Albumin, g/dL 4.45 (4.1–4.75) 4.5 (3.85–4.6) — 0.617
   AST, IU/L 55 (24.5–84) 22 (19.5–24) — <0.001
   ALT, IU/L 42.5 (15.5–98.5) 13.5 (12–20.5) — 0.003
   GGT, IU/L 60.5 (12.5–131) 12 (10–17) — <0.001
   APRI 0.42 (0.22–1.25) 0.22 (0.17–0.25) — 0.002
Medication n (%)
   UDCA 20(83) 0 (0) — <0.001
   SASP 13 (54) 1 (6) — 0.002
   Mesalazine 5 (21) 14 (88) — <0.001
   Immunosuppresive 9 (38) 10 (63) — 0.220
   Steroids 6 (25) 2 (13) — 0.439
   Probiotics 5 (21) 6 (38) — 0.277
Table 1. Demographics and characteristics of the PSC, UC, and HC subjects used. ALT, alanine 
aminotransferase; AST, asparate aminotransferase; APRI, AST to platelet ratio index; GGT, γ-glutamyl 
transferase; IBD, inflammatory bowel disease; IBD-U, inflammatory bowel disease unclassified; IQR, 
interquartile range; PUCAI, pediatric ulcerative colitis activity index; SASP, salazosulfapyridine; UDCA, 
ursodeoxycholic acid.
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To explore the taxa contributing to differences between any pair of the three groups, we generated random 
forest (RF) models using the AUC-RF package41. All receiver operating characteristic (ROC) curves were based 
on the out-of-bag (OOB) error rates in the RF models. We used the area under the curve (AUC) of these ROC 
curves to find the combination of multiple taxa contributing most to the discrimination of the three groups from 
the 29 abundant genera with relative mean abundances of >0.1%. The best model was selected according to the 
best OOB-AUC, which was observed for eight and six genera between the PSC and HC groups, and the PSC and 
UC groups, respectively (Fig. 3A).
Among these selected genera, four genera (Haemophilus, Streptococcus, Aggregatibacter and Oribacterium) 
were the common contributors to distinguish the PSC from both the HC and UC groups (Fig. 3B,C and 
Supplementary Fig. S3A). Four genera (Rothia, Prevotella, Solobacterium, and Eubacterium) contributed to dis-
tinguishing the PSC from the HC group (Fig. 3B, Supplementary Fig. S3B), and the two genera Leptotrichia and 
Alloprevotella contributed to distinguishing the PSC from the UC group (Fig. 3C, Supplementary Fig. S3C). These 
results were further confirmed by evaluating the mean AUC of 10-fold cross-validation repeated 20 times, which 
Figure 1. Comparison of the salivary microbiota of the PSC, UC, and HC subjects. Samples from 24 PSC 
(red), 16 UC (green) and 24 HC (blue) subjects are shown. (A) The observed and the Chao 1-estimated OTU 
numbers, and the Shannon’s index of salivary microbiota from the three groups. (B) Weighted UniFrac-PCoA 
and (C) unweighted UniFrac-PCoA of salivary microbiota from the three groups. OTU, operational taxonomic 
unit; PCoA, principal coordinate analysis.
Category No. of subjects
Weighted UniFrac Unweighted UniFrac
R2 p-value Adjusted p-value R2 p-value Adjusted p-value
PSC vs. UC PSC:24UC:16 0.04912 0.04496 0.04496 0.03222 0.06893 0.1544
PSC vs. HC PSC:24HC:24 0.04403 0.03097 0.04496 0.02567 0.1029 0.1544
UC vs. HC UC:16HC:24 0.0638 0.01800 0.04496 0.02723 0.2847 0.2847
Table 2. Permutational multivariate analysis of variance in salivary microbiota samples among the PSC, UC 
and HC groups. The adjusted p-values were adjusted for multiple testing by Benjamin-Hochberg procedure. 
Significant p-values are in bold.
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showed a mean AUC of 0.7423 between the PSC and HC groups, and 0.8756 between the PSC and UC groups 
(Table 3).
The principal component analysis (PCA) using the RF-selected genera more clearly distinguished the PSC 
from the HC and UC groups than the PCA using the 29 genera with the mean abundance >0.1% (Supplementary 
Fig. S4). Similarly, a best mean AUC of 0.6452 was obtained between the UC and HC groups in the 10-fold 
cross-validation of the RF-selected genera (Table 3).
At a finer species level, we used 95 species with relative mean abundances of >0.1% to build the first RF. The 
best model was selected from the best OOB-AUC value, which was observed for 16 and 11 species between the 
PSC and HC groups, and between the PSC and UC groups, respectively (Fig. 3D). The three species Oribacterium 
sp. ACB1, Lachnospiraceae oral taxon 107, and Haemophilus parainfluenzae were the common species to distin-
guish PSC from both the HC and UC groups (Fig. 3E,F and Supplementary Fig. S5A). These species also exhibited 
significant differences in the relative abundance between the PSC and HC groups and between the PSC and UC 
groups (Supplementary Fig. S5A).
Of the 16 species, 13 (Haemophilus sputorum, Leptotrichia BU064, Prevotella DO039, Atopobium sp. ICM58, 
Rothia mucilaginosa, Veillonella sp. 3_1_44, Solobacterium moorei, Granulicatella adiacens, Streptococcus san-
guinis, Streptococcus genomosp. C5, Actinomyces sp. ICM39, TM7 oral taxon 352 and [Eubacterium] infirmum) 
were the species distinguishing the PSC group from the HC group (Fig. 3E, Supplementary Fig. S5B). Of the 11 
species, eight (Haemophilus haemolyticus, Streptococcus sp. M143, Porphyromonas CW034, Prevotella sp. oral 
taxon 317, Streptococcus parasanguinis, Alloprevotella rava, Neisseria mucosa, and Streptococcus cristatus) were the 
species distinguishing the PSC group from the UC group (Fig. 3F, Supplementary Fig. S5C).
The mean AUC of the 10-fold cross-validation repeated 20 times was 0.8011 between the PSC and HC groups 
and 0.7626 between the PSC and UC groups (Table 3). The PCA using the RF-selected species showed clear seg-
regation between the PSC and HC groups, and between the PSC and UC groups (Supplementary Fig. S6). These 
specie-level contributors were further confirmed by a heatmap of the abundance of OTUs in the individuals 
(Supplementary Fig. S7). Similarly, a mean AUC of 0.5314 was obtained between the UC and HC groups in the 
10-fold cross-validation (Table 3).
Discussion
We compared salivary microbiota from age-matched pediatric-onset PSC patients, UC patients without PSC, and 
healthy individuals by using the enumerated 16S rRNA gene sequence data. The results indicated that compared 
to the healthy controls, the species richness of the PSC and UC salivary microbiota was not significantly changed. 
However, the overall structure of the PSC and UC salivary microbiota exhibited microbial dysbiosis compared to 
that of the healthy controls, and the observed dysbiosis was represented by significant changes in the abundance 
of several genera and species.
When we focused on the differences in the salivary microbiota between the PSC and UC groups, we observed 
significant differences in the abundance of two genera assigned to Haemophilus and Oribacterium and some 
species belonging to Haemophilus, Oribacterium, and Lachnospiraceae between the two groups. On the other 
hand, we observed previously that the abundance of Faecalibacterium, Ruminococcus and Roseburia genera was 
significantly different in the gut microbiota between the same PSC and UC individuals as those in the present 
study2. These data suggested almost no taxonomical similarity in the dysbiosis of salivary and gut microbiota 
between the PSC and UC groups, whereas larger numbers of species were different between them in the salivary 
Figure 2. Comparison of the bacterial composition among the PSC, UC, and HC groups. (A) The average 
microbial abundance of the 16 dominant genera with the relative mean abundances of >0.5% are represented. 
All others are summed into the category “others.” (B) Fold-change of the 16 dominant genera in PSC/HC and 
UC/HC comparisons, which are calculated by dividing the mean relative abundance (%) of each genus in the 
PSC and UC groups by that in the HC group, respectively. The mean abundance (%) in the HCs is shown in 
parentheses. Horizontal axis: The fold-change displayed in log10. Horizontal bars: The fold-change between 
PSC and HC (red) and between UC and HC (green). *p < 0.05, **p < 0.01, and ***p < 0.001 based on the 
Kruskal-Wallis test followed by the Steel-Dwass test for multiple comparisons.
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microbiota than the gut microbiota. Interestingly, the PSC fecal microbiota were characterized by a significant 
enrichment of S. parasanguinis2, which was also one of the contributing species discriminating the PSC from the 
UC salivary microbiota in the present study (Fig. 3F), but a significant difference was not observed between them 
(Supplementary Fig. S5C).
The large differences observed between the PSC and UC salivary microbial communities prompted us to 
investigate the potential of the microbiota as novel biomarkers discriminating PSC and UC patients. The 
cross-validation using salivary microbiota data identified several genera and species efficiently distinguishing the 
PSC patients from the healthy controls, and from the UC patients (Fig. 3, Table 3). Some of these AUC values were 
substantially higher than those reported in a study in which a combination of several gut species distinguished 
PSC from healthy individuals with an AUC of 0.78, and from UC with an AUC of 0.8219. We thus anticipate that 
salivary microbes can also be used as diagnostic biomarkers distinguishing PSC from healthy individuals and UC 
patients, similarly to gut microbes. Notably, since all the PSC patients in our cohort were associated with IBD, 
the identified salivary microbial biomarkers may also be efficient for distinguishing IBD patients with PSC from 
those without PSC.
Bajaj et al. reported decreased abundances of the families Lachnospiraceae and Ruminococcaceae in the sali-
vary microbiota of patients with liver cirrhosis compared to healthy controls25. In contrast, although PSC is also a 
Figure 3. Random forest (RF) analysis of the salivary microbiota in the three subject groups. RF is performed at 
the genus-level (A–C) and at the species level (D–F). The best RF model with the highest AUC is indicated by a 
red circle in the PSC-HC comparison (A), and a red triangle in the PSC-UC comparison (D). The taxa selected 
in the best RF model are shown in (B,E) for the PSC-HC comparison and in (C,F) for the PSC-UC comparison. 
The bars indicate the mean decrease Gini, and the colors indicate the fold-change, which were calculated by 
dividing the mean relative abundance (%) of each genus and species in the PSC by that in the HC group (B,E) 




PSC vs. UC 0.8756 0.7626
PSC vs. HC 0.7423 0.8011
UC vs. HC 0.6452 0.5314
Table 3. The mean area under the curve (AUC) of salivary microbiota samples among the PSC, UC, and HC 
groups. The mean AUCs of the 10-fold cross-validation process repeated 20 times using the best RF model are 
shown.
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disease that eventually progresses to liver cirrhosis, the abundance of Lachnospiraceae was significantly increased 
in our PSC salivary samples compared to the UC and healthy control samples. This opposite change in the abun-
dance of the family Lachnospiraceae in salivary microbiota between the two diseases may be due largely to the 
increase in the genus Oribacterium belonging to the family Lachnospiraceae in the PSC group and the reduction 
of this genus in the UC group compared to the healthy controls. Oribacterium was also shown to be one of the 
RF-selected genera contributing to the discrimination of PSC from UC.
Additionally, at the species level, two species (Lachnospiraceae oral taxon 107 and Oribacterium sp. ACB1, 
both belonging to the family Lachnospiraceae) were markedly enriched in the present pediatric-onset PSC group 
compared to the UC and healthy control groups, and were shown to be the species contributing to the discrimina-
tion of the two groups. Similar to the pediatric-onset PSC patients analyzed here, the family Lachnospiraceae was 
increased in the salivary microbiota of children with celiac disease33. On the other hand, Streptococcus sanguinis 
was concurrently enriched in celiac disease patients33, whereas this species was significantly decreased in our PSC 
group (Fig. 3E, Supplementary Fig. S6).
Oribacterium was also enriched in the microbiota of the tongue coat in patients with liver cancer, in which 
Oribacterium and Fusobacterium gave AUCs of 0.8137 and 0.7749 for distinguishing patients with liver cancer 
from healthy subjects, respectively42. Since PSC was also shown to have a risk for the development of liver cancer43 
and its salivary microbiota composition is similar to that of the tongue and other intraoral microbiota44,45, further 
studies are needed to clarify the differences in salivary and tongue microbiota between these two hepatic diseases.
Several papers have described the potential of salivary microbes as biomarkers for disease. For example, a 
combination of two salivary species identified as metagenomic linkage groups separated rheumatoid arthritis 
patients from healthy subjects with an AUC of 0.81435. In another study, a combination of two salivary species, 
Neisseria elongata and Streptococcus mitis, was reported to be the biomarker discriminating pancreatic cancer 
patients from healthy controls with an AUC of 0.9028. A combination of two salivary genera, Capnocytophaga and 
Veillonella, yielded AUCs of 0.86 and 0.80 in distinguishing squamous cell carcinoma and adenocarcinoma in 
patients with lung cancer from healthy controls, respectively30.
These previous studies and our present investigation consider the combination of more than two different 
genera or species to be candidates for microbial biomarkers. We note that none of the microbial combinations 
reported to date overlap between diseases, suggesting that physiological states in these systemic diseases have 
different influences on the salivary microbiota. The alteration of salivary microbial profile would thus be a potent 
indicator that is sensitive to the host’s physiological changes in systemic disease.
In the diagnoses of clinical samples, medical treatments such as the administration of antibiotics are an issue 
to be considered because such treatments sometimes strongly change the microbial community structure, regard-
less of disease. We use exclusively SASP for gastrointestinal lesions in PSC, based on several reports46,47, and we 
observed that SASP treatment significantly changed the gut microbiota due to an antibacterial agent generated 
by the metabolism of SASP in the gut2. Therefore, a high tolerance of salivary microbiota to medical treatments is 
desired for the development of accurate diagnostics using the microbiota as biomarkers. In the present study, no 
significant difference in the salivary microbiota was observed in the PCS and UC salivary samples treated with 
SASP and mesalazine, in agreement with the previous report demonstrating the high stability of salivary micro-
biota compared to gut microbiota under the exposure of antibiotics48.
One of the limitations in our study is the small sample size. Pediatric-onset PSC is a rare disease, and it is 
difficult to collect large numbers of samples. To address this problem, we used cross-validation based on the best 
RF model to identify and validate microbial species that discriminate two groups with high fidelity to minimize 
overfitting. This may be a powerful strategy for analyses in which the number of samples is limited. In addition, 
sampling time in a day may also be considered for the accurate diagnosis because of considerable changes in the 
salivary microbiota composition due to the circadian rhythm44.
Our present findings demonstrated the potential of salivary microbes as tools for the noninvasive diagnosis 
of pediatric-onset PSC. However, it remains unknown whether the microbial markers identified here are also 
globally applicable to adult PSC patients and to PSC patients with different IBD status, genetic backgrounds, 
geographic locations, and dietary styles.
Methods
Sample collection and DNA extraction. All subjects were instructed to provide fresh saliva in a test 
tube during the daytime on the day of sample collection. The subjects were antibiotic-free for ≥2 weeks prior to 
sampling, except for SASP in the PSC group. The subjects were prohibited from eating or drinking for 2 hr prior to 
sample collection, but there was no restriction regarding the type of food eaten before that period. The saliva sam-
ples were immediately sealed in an AnaeroPack-Anaero (a plastic bag containing a disposable oxygen-absorbing 
and carbon dioxide-generating agent; Mitsubishi Gas Chemical, Tokyo) and then transported on ice to the labo-
ratory within 24 hr. At the laboratory, the saliva samples were suspended in 20% glycerol and phosphate-buffered 
saline (PBS), and then immediately frozen in liquid nitrogen and stored at −80 °C until further analysis49.
The isolation of bacterial DNA from the salivary samples was performed as described26. The 16S rRNA 
gene V1–V2 region was amplified by polymerase chain reaction (PCR) using the forward primer 27Fmod 
(5′-CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNNNNNNagrgtttgatymtggctcag-3′), containing 
the 454 primer A and a unique 10-bp barcode sequence for each sample (indicated by Ns), and the reverse primer 
338 R (5′-CCTATCCCCTGTGTGCCTTGGCAGTCTCAGtgctgcctcccgtaggagt-3′) containing the 454 primer 
B38. The PCR was performed using 50 μL of 1× Ex Taq PCR buffer composed of 10 mM Tris-HCl (pH 8.3), 50 mM 
KCl, and 1.5 mM MgCl2 in the presence of 250 μM dNTPs, 1 U Ex Taq polymerase (Takara Bio, Kyoto, Japan), 
forward and reverse primers (0.2 μM), and approximately 20 ng of template DNA.
Thermal cycling was performed in a 9700 PCR System (Life Technologies Japan, Tokyo) with the following 
cycling conditions: initial denaturation at 96 °C for 2 min, followed by 25 cycles of denaturation at 96 °C for 30 sec, 
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annealing at 55 °C for 45 sec, and extension at 72 °C for 1 min; and final extension at 72 °C. PCR amplicons were 
purified using AMPure XP magnetic purification beads (Beckman Coulter, Brea, CA, USA) and quantified using 
the Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies Japan). An equal amount of each PCR ampli-
con was mixed and subjected to sequencing with the 454 GS FLX Titanium platform (Roche Applied Science, 
Indianapolis, IN) according to the manufacturer’s instructions.
Data processing of 16S rRNA sequences. We used an analysis pipeline for the processing of the 454 
pyrosequencing data of the 16S rRNA gene V1–V2 region, as reported38. Briefly, after multiplexed sequencing 
of the 16S amplicons, sequences were assigned to samples on the basis of their barcode sequences. Reads with 
an average quality value <25, inexact matches to both universal primers, and possible chimeric reads, totally 
accounting for 43–44% of all reads, were removed (Supplementary Table S1). Among the high-quality reads, 
3,000 reads per sample were randomly chosen and used for the analysis conducted in this study.
We then sorted the selected reads with the average quality value and grouped them into OTUs by clustering 
using the UCLUST algorithm with a 96% identity threshold26. Taxonomic assignments for each OTU were made 
by similarity searching against the publicly available 16S (RDP and CORE) and NCBI genome databases using 
the GLSEARCH program. For assignment at the phylum, family, genus, and species levels, the sequence similarity 
thresholds of 70%, 90%, 94% and 96% were respectively applied. All of the high-quality 16S V1–V2 sequences 
analyzed in this study were deposited into the DDBJ/GenBank/EMBL database (accession no. DRA005698).
Data analysis. Comparisons of the categorical variables were done using the Chi-squared test, Fisher’s exact 
test, Mann-Whitney U-test, and Kruskal-Wallis test where appropriate. The UniFrac distance was used for the 
assessment of the dissimilarity (distance) between any pair of samples50. We performed a principal coordinate 
analysis (PCoA) to visualize the similarities or dissimilarities in the microbiome structure in the UniFrac analysis. 
We conducted a PERMANOVA to compare the overall microbiome structure, and the p-values were adjusted for 
multiple testing by the Benjamin-Hochberg procedure. We used the observed and Chao 1-estimated OTU num-
bers and Shannon’s index to evaluate the richness and diversity of the overall microbial community. The similarity 
of the relative abundance at the phylum, family, genus, and species levels was assessed using the Kruskal-Wallis 
test followed by the Steel-Dwass test for multiple comparisons.
Random forest (RF) models were generated using the AUC-RF41 package. All receiver operating character-
istic (ROC) curves presented for RF models were based on the out-of-bag (OOB) error rates. The area under 
the curve (AUC) of these ROC curves was used to find the most discriminatory variables (genera or species). 
The first RF was build, using all the variables, which provides the initial ranking of the variables according to 
its importance according to the mean decrease Gini. In the subsequent steps, 5% of the less important variables 
according to the initial ranking were eliminated. The RF was built with the remaining variables, and the AUC 
based on OOB predictions (OOB-AUC) of the RF was computed in each model. The best model was selected with 
the best OOB-AUC value. The best RF model was further confirmed by evaluating the mean AUC of a 10-fold 
cross-validation repeated 20 times using the AUC-RF41 package. All of these analyses were performed using the R 
software program (v3.3.1). All methods were carried out in accordance with relevant guidelines and regulations.
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